“The Acute Pain Market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics”
The Acute Pain market report provides current treatment practices, Acute Pain emerging drugs, market share of individual therapies, and current and forecasted 7MM Acute Pain market size from 2019 to 2032. The report also covers current Acute Pain treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Acute Pain Market Research Report
- The increased number of Acute Migraine cases, along with the emerging treatment, is likely to contribute directly to the market growth during the forecast period (2023-2032).
- The leading companies working in the Acute Pain Market include Hyloris Pharmaceuticals, AFT Pharmaceuticals, Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals, Taiwan Liposome Company (TLC), Medical Developments International (MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals, Teikoku Pharma USA, PainReform, Nevakar, and others.
- Promising Acute Pain Pipeline Therapies in the various stages of development include Methoxyflurane, Diclofenac 50, Tramadol 50, Tapentadol oral solution 20 mg/mL, Diclofenac Sodium, IV Acetaminophen, VX-548, HB/APAP, PBK_L1704 0.35mg, and others.
- September 2023: Vertex Pharmaceuticals Incorporated announced a study of phase 3 clinical trials for VX-548. The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
- September 2023: Elysium Therapeutics Inc. announced a study of phase 1 clinical trials for ETR028, ETR029, [ETR028 + ETR029] or HCBT. The goal of this Phase 1 clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of O2P (Oral Overdose Protected) hydrocodone prodrugs (ETR028 and ETR029) relative to hydrocodone bitartrate hemipentahydrate (HCBT) comparator following single oral doses in healthy adult subjects under fasted and fed conditions with naltrexone blockade.
- September 2023: Nobelpharma announced a study of phase 3 clinical trials for NPC-06. To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in patients with pain associated with acute herpes zoster in a placebo-controlled, double-blind, parallel-group, comparative manner.
Discover more about therapies set to grab major Acute Pain Market Share @ Acute Pain Market Size
Acute Pain Overview
Pain is an uncomfortable sensation that usually signals an injury or illness and tells the body that something is wrong. It is a sensory symptom of tissue damage or disorder that can be either acute or chronic. International Association for the Study of Pain (IASP) defines acute pain as sudden pain that starts sharp or intense and is a warning sign of disease or threat to the body.
Acute Pain Epidemiology Segmentation in the 7MM
- Total Acute Pain Incidence
- Total Acute Pain Diagnosed Incident Cases
- Acute Pain Type-specific Diagnosed Incident Cases
- Acute Pain Severity-specific Diagnosed Incident Cases
- Total Acute Pain Treated Cases
Download the report to understand which factors are driving Acute Pain Epidemiology Trends @ Acute Pain Epidemiological Insights
Acute Pain Treatment Market
Acute Pain treatment decisions are based on the type of migraine (episodic or chronic), the level of impairment they cause, previous treatment history, and patient preferences. In addition, clinicians must consider comorbid conditions and the potential for drug interactions with existing medications during treatment selection.
Acute Pain Market Insights
Despite the availability of standard treatment guidelines across regions and the well-entrenched presence of an array of available, mostly inexpensive options, current abortive and prophylactics, there exists a high unmet need which is contrary to the popular perception. The therapies addressed in recent are not effective in all patients, have contraindications related to cardiovascular conditions in some patients, and are nonspecific or poorly tolerated in others. Response rates fall well short of 100%, and breakthrough attacks are common, accompanied by polypharmacy to achieve maximal results.
To know more about Acute Pain Treatment options, visit @ Acute Pain Drugs
Acute Pain Therapeutics Market
The overall Acute Migraine pipeline is expected to undergo a paradigm shift in the coming years owing to large scale changes in the market composition, a dynamic process that has already started taking shape since 2019. Novel compounds and improved biomarker identification led treatment targets will significantly boost the overall revenue generation during the forecast period [2023–2032] across the 7MM. The launch of various multiple-stage pipeline products will significantly revolutionize the Acute Migraine market dynamics. The emerging drug analysis along with their detailed profiling is done by the DelveInsight.
Acute Pain Market Size
The Acute Migraine market size is expected to undergo significant changes in the upcoming years due to the anticipated launch of emerging therapies such as PUR3100, TRV-250, CL-H1T several others, which are actively in development for the treatment of Acute Migraines.
Learn more about the Acute Pain Pipeline Therapies in clinical trials @ Acute Pain Market Landscape
Scope of the Acute Pain Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Acute Pain Companies- Hyloris Pharmaceuticals (NYSE:HYL.BR), AFT Pharmaceuticals (NYSE: AFP.AX), Formosa Pharmaceuticals, Concentric Analgesics, Vivozon, Vertex Pharmaceuticals (NYSE: VRTX), Taiwan Liposome Company (NYSE: TLC), Medical Developments International (NYSE: MVP), Neumentum Pharmaceuticals, Charleston Laboratories, AcelRx Pharmaceuticals (NYSE: ACRX), Teikoku Pharma USA, PainReform (NYSE: PRFX), Nevakar, and others.
- Acute Pain Pipeline Therapies- Methoxyflurane, Diclofenac 50, Tramadol 50, Tapentadol oral solution 20 mg/mL, Diclofenac Sodium, IV Acetaminophen, VX-548, HB/APAP, PBK_L1704 0.35mg, and others.
- Acute Pain Market Dynamics: Acute Pain Market Drivers and Barriers
- Acute Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Acute Pain Drugs in development @ Acute Pain Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Acute Pain Market Report Introduction
- Acute Pain Market Overview at a Glance
- Acute Pain Executive Summary
- Acute Pain Epidemiology and Market Methodology
- Disease Background and Overview: Acute Pain
- Patient Journey
- Acute Pain Epidemiology and Patient Population
- Key Endpoints in Acute Pain Clinical Trials
- Acute Pain Marketed Drugs
- Acute Pain Emerging Drugs
- Conjoint Analysis
- Acute Pain: Market Analysis
- Acute Pain KOL Views
- Acute Pain Unmet needs
- Acute Pain SWOT Analysis
- Acute Pain Market Access and Reimbursement
- DelveInsight Capabilities
- About DelveInsight
Top Selling Market Research Reports in 2023
Acute Pharyngitis Market | Bartonellosis Market | Concussions Market Size | Allergic Rhinoconjunctivitis Market | Atherectomy Devices Market | Heavy Metal Poisoning Markets | Nipah Virus Infection Market | Central Venous Catheters Market | Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Rhino Conjunctivitis Market | Defibrillators Market | Pulse Oximeters Market | Angioedema Market | Alopecia Aerata Market | Alport Syndrome Market | Foot And Ankle Devices Market | Car T Therapy For Acute Lymphoblastic Leukemia All Market | Allergic Rhinoconjunctivitis Market | Nipah Virus Infection Market | Postsurgical Pain Market | Ventricular Dysfunction Market | Scleroderma Market | Atypical Teratoid Rhabdoid Tumors Market | Capnography Device Market | Chemotherapy Induced Anemia Market | Duchenne Muscular Dystrophy Market | Neuroblastoma Market | Abetalipoproteinemia Market | Acute Pulmonary Embolism Market | Aesthetic Implants Market | Athelete’s Foot Market | Cardiac Amyloidosis Market | Cardiotoxicity Market | Cluster Headache Market | Crohns Disease Cd Market | Ctcl Market | Dermal Erythema Market | Exocrine Pancreatic Insufficiency Market | Neuroprosthetics Market | Nsclc Market | Osteoarthritis Market | Urolithiasis Market | Granulomatosis With Polyangiitis Market
Read More about Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.